Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

TNFRSF4 Protein (AA 29-216) (His tag)

TNFRSF4 Origine: Humain Hôte: HEK-293 Cells Recombinant >90 % as determined by SDS-PAGE. Active
N° du produit ABIN2181571
  • Antigène Voir toutes TNFRSF4 Protéines
    TNFRSF4 (Tumor Necrosis Factor Receptor Superfamily, Member 4 (TNFRSF4))
    Type de proteíne
    Recombinant
    Activité biologique
    Active
    Attributs du protein
    AA 29-216
    Origine
    • 27
    • 17
    • 5
    • 5
    • 3
    • 2
    • 1
    Humain
    Source
    • 36
    • 8
    • 4
    • 4
    • 2
    • 1
    • 1
    • 1
    • 1
    HEK-293 Cells
    Purification/Conjugué
    Cette TNFRSF4 protéine est marqué à la His tag.
    Séquence
    AA 29-216
    Attributs du produit
    This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 22 kDa. The protein migrates as 40-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
    Pureté
    >90 % as determined by SDS-PAGE.
    Stérilité
    0.22 μm filtered
    niveau d'endotoxine
    Less than 1.0 EU per μg by the LAL method.
    Top Product
    Discover our top product TNFRSF4 Protéine
  • Restrictions
    For Research Use only
  • Format
    Lyophilized
    Buffer
    PBS, pH 7.4
    Conseil sur la manipulation
    Please avoid repeated freeze-thaw cycles.
    Stock
    -20 °C
    Stockage commentaire
    No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).
  • Upadhyaya, Lahdenranta, Hurov, Battula, Dods, Haines, Kleyman, Kristensson, Kublin, Lani, Ma, Mudd, Repash, Van Rietschoten, Stephen, You, Harrison, Chen, McDonnell, Brandish, Keen: "Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist." dans: Journal for immunotherapy of cancer, Vol. 9, Issue 1, (2021) (PubMed).

    Simons, Lim, Carter, Wagner, Wayham, Adler, Johnson: "Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR." dans: mAbs, Vol. 12, Issue 1, pp. 1803646, (2020) (PubMed).

    Fromm, de Silva, Johannes, Patel, Hornblower, Schreiber: "Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy." dans: Journal for immunotherapy of cancer, Vol. 6, Issue 1, pp. 149, (2018) (PubMed).

  • Antigène
    TNFRSF4 (Tumor Necrosis Factor Receptor Superfamily, Member 4 (TNFRSF4))
    Autre désignation
    OX40 (TNFRSF4 Produits)
    Synonymes
    TNFRSF4 Protein, ACT35 Protein, CD134 Protein, Ly-70 Protein, Ox40 Protein, TXGP1L Protein, Txgp1 Protein, OX40 Protein, TNF receptor superfamily member 4 Protein, tumor necrosis factor receptor superfamily, member 4 Protein, TNFRSF4 Protein, Tnfrsf4 Protein
    Sujet
    Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.
    Poids moléculaire
    22.0 kDa
    NCBI Accession
    NP_003318
    Pathways
    Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints
Vous êtes ici:
Support technique